Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2026)

Heron Therapeutics filings provide 6 years of Non-Current Debt readings, the most recent being $108.3 million for Q1 2026.

  • On a quarterly basis, Non-Current Debt rose 329.57% to $108.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $108.3 million, a 329.57% increase, with the full-year FY2025 number at $107.9 million, up 331.15% from a year prior.
  • Non-Current Debt hit $108.3 million in Q1 2026 for Heron Therapeutics, roughly flat from $107.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $108.3 million in Q1 2026 to a low of $24.0 million in Q3 2023.
  • Median Non-Current Debt over the past 4 years was $24.9 million (2024), compared with a mean of $49.6 million.
  • The widest YoY moves for Non-Current Debt: up 332.93% in 2025, down 3.13% in 2025.
  • Heron Therapeutics' Non-Current Debt stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024, then soared by 331.15% to $107.9 million in 2025, then rose by 0.38% to $108.3 million in 2026.
  • The last three reported values for Non-Current Debt were $108.3 million (Q1 2026), $107.9 million (Q4 2025), and $107.5 million (Q3 2025) per Business Quant data.